Several clinical trials have shown significant CV benefits of GLP-1 RAs in patients with T2D who were at high risk of CV events, with many of these individuals also taking a RAAS inhibitor at baseline [27, 36–38]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.